Proteomic identification of biomarkers related to Helicobacter pylori-associated gastroduodenal disease: challenges and opportunities.
Helicobacter pylori colonize the stomach of over half the world's population. While 80-90% H. pylori-infected individuals have clinically asymptomatic gastritis, 10-15% develop peptic ulcer, and 1-2% gastric malignancies. These variable clinical outcomes have led to an interest in prognostic indicators. The current disease paradigm suggests that host genetics and bacterial virulence both play important roles in modulating the final outcome of H. pylori infection. Elucidation of the interaction between host and bacterium is essential to clarify pathogenesis and to develop new strategies for prevention and treatment. Proteomic technology is a powerful tool for simultaneously monitoring proteins and protein variation on a large scale in biological samples. It has provided an unprecedented opportunity to survey a cell's translational landscape comprehensively, and the results may allow in-depth analyses of host and pathogen interactions. Using this high-throughput platform and taking advantage of complete sequences for both the H. pylori and the human genome in available databases, we have identified several crucial proteins that have pathogenic and prognostic potential. Among them, antibodies to AhpC and GroEs of H. pylori could be utilized for identification of patients who are at high risk of disease complications after H. pylori infection. Evolving proteomic technologies, together with appropriate clinical phenotyping and genotype information should enhance understanding of disease pathogenesis and lead to more precise prediction of variable disease outcomes. It will also facilitate development of biomarkers for diagnosis, treatment, and prevention of H. pylori infection.
Wu
Ming-Shiang
MS
Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. mingshiang@ntu.edu.tw
Chow
Lu-Ping
LP
Lin
Jaw-Town
JT
Chiou
Shyh-Horng
SH
D001426:Bacterial Proteins / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D004378:Duodenal Diseases / Q000378:metabolism / Q000382:microbiology*; D016481:Helicobacter Infections / Q000150:complications / Q000382:microbiology*; D016480:Helicobacter pylori / Q000472:pathogenicity*; D006801:Humans; D011379:Prognosis; D011506:Proteins / Q000032:analysis*; D040901:Proteomics / Q000379:methods; D013272:Stomach Diseases / Q000378:metabolism / Q000382:microbiology*; D013274:Stomach Neoplasms / Q000378:metabolism / Q000382:microbiology; D037521:Virulence Factors / Q000032:analysis
D001426:Bacterial Proteins; D015415:Biomarkers; D011506:Proteins; D037521:Virulence Factors